Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDC-1801
- Development stage
- Phase 1
- Lead developer
- Sareum
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SDC-1801 is a small molecule, orally administered dual inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), both members of the JAK family of proteins. It is being developed by Sareum as a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. The drug acts by inhibiting TYK2 and JAK1 signaling pathways, which are implicated in the pathogenesis of several immune-mediated disorders. Preclinical and early clinical studies have demonstrated that SDC-1801 has a favorable safety profile, with no serious adverse events reported in Phase 1 trials. The compound has shown potential for once-daily oral dosing due to its pharmacokinetic properties[2][4][5][6][9].
02
Targets
JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on SDC-1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SDC-1801.